Flex Pharma $FLKS announced its clinical development plan for FLX-787 for the treatment of nocturnal leg cramps (NLCs). Once it receives a feedback from the FDA, it plans a parallel design Phase 2 study, which should start in H1 2017 after its Investigational New Drug (IND) application has been filed and accepted.